Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Systematic Evaluation of Combination Strategies with Rezatapopt in p53 Y220C-Mutant Cancer Models.

Rezatapopt (PC14586), a first-in-class Y220C-selective p53 reactivator, demonstrates single-agent clinical efficacy; however, combinatorial strategies may enhance clinical outcomes. Here, we evaluated rezatapopt in combination with standard-of-care agents (chemotherapy and bevacizumab), murine double minute 2 (MDM2) in...

Tamer Ahmed, Erin E. Michaud, Li-Zhong Xu et al. · 0 citations
Aug 2026

Targeting EP2 overcomes osimertinib-tolerant persisters through metabolic and inflammatory reprogramming in non-small cell lung cancer.

Although osimertinib is an effective third-generation EGFR inhibitor for EGFR-mutant NSCLC, the emergence of acquired resistance continues to limit its long-term clinical benefit. However, the early cellular adaptations that allow residual tumor cells to survive osimertinib exposure are not fully understood. Here, we c...

Haiyang Yu, Ling Lu, Xue Hu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.